Skip to main content
S&P 5007,606.88+0.28%DOW52,040.67-0.10%NASDAQ26,152.90+0.66%BTC$75,693.00-0.62%ETH$2,389.74-0.93%GOLD$4,388.40+1.28%OIL$102.60-3.05%
Smart Investors Daily
PA

NASDAQ · PALI

Palisade Bio, Inc.

Healthcare · Biotechnology

$2.02

Down-$0.17 (-8.44%)

Updated Sep 16, 2026, 5:12 PM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
327.06M
P/E ratio
-1.46
Dividend yield
0.00%
52-week range
$0.55 – $2.86
Volume
4.49M
Avg. volume
8.34M

Price performance

PALI price history

1M range · 20 trading sessions · Daily adjusted prices

PALI closed at $2.02 after 20 trading sessions, down 1.23% for the selected period.

Last close
$2.02
Period change
-1.23%
Period low
$1.95
Period high
$2.20
Daily close
View OHLC price history
PALI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$2.05$2.06$1.96$2.0154.49M
Sep 14, 2026$2.05$2.11$2.02$2.051.81M
Sep 11, 2026$2.05$2.10$2.02$2.062.4M
Sep 10, 2026$2.05$2.11$2.01$2.012.65M
Sep 9, 2026$2.17$2.21$2.05$2.052.77M
Sep 8, 2026$2.09$2.235$2.08$2.203.53M
Sep 4, 2026$2.03$2.12$2.00$2.091.76M
Sep 3, 2026$2.01$2.05$1.97$2.0451.09M
Sep 2, 2026$1.96$2.005$1.95$1.99731.45K
Sep 1, 2026$1.96$1.98$1.915$1.96879.45K
Aug 31, 2026$2.02$2.02$1.93$1.951.65M
Aug 28, 2026$2.10$2.1116$1.99$2.002.13M
Aug 27, 2026$2.12$2.16$2.095$2.11899.22K
Aug 26, 2026$2.06$2.135$2.032$2.131.19M
Aug 25, 2026$2.02$2.10$1.98$2.072.07M
Aug 24, 2026$2.10$2.10$2.00$2.011.62M
Aug 21, 2026$2.09$2.135$2.08$2.101.07M
Aug 20, 2026$2.14$2.15$2.03$2.061.32M
Aug 19, 2026$2.10$2.19$2.085$2.162.29M
Aug 18, 2026$2.15$2.15$2.01$2.042.29M

Latest PALI news

The latest Smart Investors Daily articles mentioning PALI.

Stock researchCompany · Overview

PALI research

Overview

Company profile and research snapshot.

Company profile

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.50
Implied upside
—
Analysts
—
PALI recent ratings
DateFirmRatingTarget
Jul 23, 2026OppenheimerOutperform—
Apr 9, 2026Wolfe ResearchOutperform—
Mar 26, 2026HC Wainwright & Co.Buy—
Feb 25, 2026StifelBuy—
Jan 9, 2026B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Palisade Bio to Participate in Upcoming Investor Conferences

Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026. Wells Fargo 2026 Healthcare Conference Dates: September 8–10, 2026Location: Boston, MassachusettsFormat: Investor meetings Morga

Benzinga · Aug 10, 2026

Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same period last year. The

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By